Journal article
Plasma cell-free dna profiling of pten-pi3kakt pathway aberrations in metastatic castration-resistant prostate cancer
EM Kwan, C Dai, H Fettke, C Hauser, MM Docanto, P Bukczynska, N Ng, S Foroughi, LJK Graham, K Mahon, W Tan, X Wang, Z Zhao, T Zheng, K Zhou, J Yu, P Du, LG Horvath, S Jia, M Kohli Show all
JCO Precision Oncology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021
DOI: 10.1200/PO.20.00424
Abstract
PURPOSE Tumor tissue frommetastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs in plasma cell-free DNA (cfDNA) has proven to be challenging. With emerging data supporting Akt inhibition in PTEN-deficientmCRPC, we profiled PTENPI3K- AKT pathway aberrations in patients with mCRPC using a novel cfDNA assay optimized for CNV detection. METHODS A next-generation sequencing-based cfDNA assay was used to profile 231 patients with mCRPC from two independent cohorts (Australian, n = 78; United States, n = 153). PTEN-PI3K-AKT pathway genomic aberrations were correlated with clinical outcomes, inclu..
View full abstractGrants
Awarded by Astellas Pharma US
Funding Acknowledgements
E.M.K.: NHMRC Postgraduate Scholarship, Monash University Postgraduate Publications Award. H.F.: Australian Government Research Training Program (RTP) Scholarship, Monash University Postgraduate Publications Award. K.M.: Movember/Prostate Cancer Foundation of Australia Clinical Scientist Fellow. L.G.H.: Astellas Investigator-Initiated Grant, Cancer Institute NSW Translational Program Grant, Twin Towns services Community Foundation Grant. M.K.: National Institute of Health-RO1-CA212097. A.A.A.: NHMRC Project Grant (GNT1098647), Victorian Cancer Agency Clinical Research Fellowship (CRF14009), Astellas Investigator-Initiated Grant.